Etoricoxib Versus Ibuprofen in Third Molar Extraction Pain
- Registration Number
- NCT00855777
- Lead Sponsor
- Universita di Verona
- Brief Summary
The aim of this study is to evaluate the analgesic efficacy of etoricoxib compared with a well known and widely used non-steroid antinflammatory drug, ibuprofen, in third molar extraction pain. At this time, there are no data about the efficacy of etoricoxib for reducing pain following dental extraction.
This will be a single center, randomized, double-blind study, in which patients with moderate to severe pain following third molar extraction will be randomized to receive etoricoxib (120 mg in a single dose + 2 dose of placebo pro day for 3 days) or ibuprofen (1800 mg in 3 doses pro day for 3 days). Paracetamol plus codeine will be used as rescue medication. Pain assessment will be performed using a 11-point pain intensity scale (0 = no pain and 10 = worster pain) during the first 3 days after dental extraction. Patients will be enrolled 15 days before the dental extraction. During enrollment visit a complete clinical evaluation with particular attention for potential exclusion criteria (e.g. hypertension and cardiovascular risk factors) as well as blood analyses will be performed. A follow-up visit will be performed 15 days after the dental extraction. Tolerability will be assessed through recording of adverse events.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 110
- subjects with age > 18 years
- in good health status (assessed in occasion of enrollment visit) without any major systemic illness
- candidate to third molar extraction and presenting local pain within 2 hours after dental extraction
- patients with any major systemic illness
- patients with a clinical history of drug abuse
- patients with hypertension and/or a condition of increased cardiovascular risk
- pregnant or lactating women
- patients with a history of hypersensitivity/allergy to analgesic drugs, including classical NSAID or coxibs
- patients with either high levels of liver enzymes (major of 1.5x the upper limit of reference interval) or of creatinine(major of 1.2x the upper limit of reference interval)
- patients with either a history of peptic ulcer or of haemorrhagic diathesis
- patients who can not ensure an adequate compliance for the study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Etoricoxib etoricoxib Etoricoxib 120 mg/day x 3 days Ibuprofen ibuprofen Ibuprofen 1800 mg/day x 3 days
- Primary Outcome Measures
Name Time Method analgesic efficacy 3 days
- Secondary Outcome Measures
Name Time Method side effects 3 days